Marshall Wace LLP Purchases Shares of 18,461 Korro Bio, Inc. (NASDAQ:KRRO)

Marshall Wace LLP acquired a new stake in shares of Korro Bio, Inc. (NASDAQ:KRRO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 18,461 shares of the company's stock, valued at approximately $703,000. Marshall Wace LLP owned about 0.20% of Korro Bio at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Korro Bio in the fourth quarter worth $53,000. AlphaQuest LLC lifted its position in shares of Korro Bio by 23.2% in the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company's stock worth $83,000 after buying an additional 412 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company's stock valued at $129,000 after buying an additional 831 shares during the last quarter. Legal & General Group Plc increased its stake in Korro Bio by 664.1% in the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company's stock worth $165,000 after acquiring an additional 3,759 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in shares of Korro Bio during the 4th quarter worth approximately $211,000. 13.18% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on KRRO. Oppenheimer initiated coverage on shares of Korro Bio in a research note on Friday, January 10th. They issued an "outperform" rating and a $155.00 price objective for the company. Cantor Fitzgerald upgraded Korro Bio to a "strong-buy" rating in a research report on Tuesday, April 29th. Chardan Capital assumed coverage on Korro Bio in a research note on Wednesday, April 16th. They issued a "buy" rating and a $25.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $115.00 price objective on shares of Korro Bio in a report on Thursday, March 20th. Finally, Royal Bank of Canada dropped their price objective on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 19th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $114.63.

Korro Bio Price Performance

NASDAQ KRRO traded down $2.61 on Tuesday, hitting $15.06. The stock had a trading volume of 58,385 shares, compared to its average volume of 96,885. The business's fifty day moving average price is $18.48 and its 200 day moving average price is $35.64. The stock has a market cap of $141.43 million, a price-to-earnings ratio of -1.61 and a beta of 2.66. Korro Bio, Inc. has a 52-week low of $11.13 and a 52-week high of $98.00.

Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.33) by $0.07. The business had revenue of $2.27 million for the quarter. As a group, sell-side analysts anticipate that Korro Bio, Inc. will post -9.52 EPS for the current year.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).